B. Braun/Trendlines partnership leads to $5 million investment for ApiFix

Editor’s note: News of the ApiFix investment appeared in Becker’s Spine Review, Mass Device, Deal StreetAsia, NextInsight, The Business Times, Globes EnglishHaaretz; GeekTime, and Calcalist (both in Hebrew); finanzen.net (German).


Trendlines and ApiFix jointly announced B. Braun’s lead position in ApiFix’s B round financing. B. Braun’s Aesculap division invested US$2.8 million in the US$5 million round, which is to close by end of 2016.

apifix cardApiFix is disrupting the scoliosis device market with its minimally invasive, non-fusion spinal implant system for the correction of Adolescent Idiopathic Scoliosis (AIS). Traditional surgical correction is a highly invasive procedure involving fusion, which results in a rigid spine and low patient quality of life. The ApiFix system is implanted in a minimally invasive procedure and does not require fusion, thereby maintaining spine flexibility and high quality of life.

The global market for ApiFix is over US$1.15 billion.¹ ApiFix received the CE mark in 2012 and is marketing its device in Europe. More than 100 operations have been performed with the ApiFix implant; first patients are now four years post-surgery, with excellent clinical results and patient quality of life.

ApiFix CEO Eran Feldhay, M.D., remarked: “Clinical experience with ApiFix’s non-fusion correction system for the treatment of scoliosis is growing. We have now completed more than 100 surgeries with overwhelmingly positive results. This funding round will support our FDA submission in the coming months and assist the expansion of our clinical and commercial activities in Europe.”

ApiFix’s founding investor and largest shareholder, Trendlines, welcomed B. Braun’s investment. Todd Dollinger, Trendlines’ Chairman and CEO, who also serves as chairman of ApiFix, said: “This round positions ApiFix for accelerated growth and brings B. Braun’s substantial experience to ApiFix’s board of directors. We look forward to B. Braun contributing to bringing ApiFix’s breakthrough scoliosis solution – and future products – to patients around the world.”

B. Braun, one of the world’s leading providers of healthcare solutions, began partnership activities with Trendlines in 2015.

Trendlines and B. Braun have established mutual deal flow to identify potential new investment opportunities and are working together in the establishment of incubators and collaboration in the development of new technologies, solutions, and products. B. Braun invested approximately US$5 million in Trendlines as a cornerstone investor in Trendlines’ 2015 initial public offering in Singapore. B. Braun and Trendlines have executed a memorandum of understanding for co-investment in Trendlines Medical Singapore, Trendlines’ first incubator outside of Israel.

Prof. Dr. Hanns-Peter Knaebel, a member of the B. Braun Management Board and CEO of their Aesculap division, commented, “Our deep interest in innovation and in bringing disruptive products to patients and the medical community drives our internal R&D efforts and, as well, brings us to search the world for investment opportunities to achieve these same goals. Our investment in ApiFix, a Trendlines’ portfolio company, further cements B. Braun and Trendlines collaboration effort.”

¹ Life Science Intelligence report on global scoliosis market